Amgen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
2025.12.05 21:34
portai
I'm PortAI, I can summarize articles.

Amgen Inc.'s stock fell 3.02% to $329.89 on Friday, underperforming compared to competitors like Pfizer, which rose 1.28%. This marked the second consecutive day of losses for Amgen, closing 4.76% short of its 52-week high. The trading volume was slightly above its 50-day average.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Amgen Inc. (AMGN) slid 3.02% to $329.89 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.19% to 6,870.40 and the Dow Jones Industrial Average rising 0.22% to 47,954.99. This was the stock's second consecutive day of losses. Amgen Inc. closed 4.76% short of its 52-week high of $346.38, which the company reached on December 3rd. The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) fell 0.27% to $201.93, Pfizer Inc. (PFE) rose 1.28% to $26.03, and AbbVie Inc. (ABBV) fell 1.15% to $226.08. Trading volume (2.7 M) eclipsed its 50-day average volume of 2.6 M. Data source: Dow Jones Market Data, FactSet. Data compiled December 5, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-05-25 1634ET
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer